---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009935"
form_type: "8-K"
ticker: "FNCHQ"
cik: "0001733257"
company_name: "Finch Therapeutics Group, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T15:10:11.098074+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Finch Therapeutics reports Q1 net loss of $24.6M; FDA lifts clinical hold on CP101

## Summary
- FDA lifted clinical hold on CP101 IND; Phase 3 PRISM4 enrollment expected in H2 2022.
- Q1 2022 net loss $24.6M vs $14.0M in Q1 2021; revenue fell due to Takeda amendment.
- Secured $55M debt facility from Hercules Capital; $15M drawn at closing.
- Workforce reduced ~20% to focus on CDI, ASD, and Takeda-partnered IBD programs.
- Cash and equivalents $106.9M as of March 31, 2022; runway into Q2 2024.

## SEC filing metadata
- accession: 0000950170-22-009935
- form_type: 8-K
- ticker: FNCHQ
- cik: 0001733257
- company_name: Finch Therapeutics Group, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733257/000095017022009935/0000950170-22-009935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733257/000095017022009935/fnch-20220516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009935
- JSON: https://secwatch.observer/filing/0000950170-22-009935.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.